Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus

This publication has 41 references indexed in Scilit:

• Linezolid
  PharmacoEconomics, 2005
• National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004
  American Journal of Infection Control, 2004
• Isolation measures in the hospital management of methicillin resistant Staphylococcus aureus (MRSA): systematic review of the literature
  BMJ, 2004
• Regional variation in the treatment and outcomes of myocardial infarction: investigating New England’s advantage
  American Heart Journal, 2003
• Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III Studies
  Antimicrobial Agents and Chemotherapy, 2003
• Safety and tolerability of linezolid
  Journal of Antimicrobial Chemotherapy, 2003
• Hematologic Effects of Linezolid: Summary of Clinical Experience
  Antimicrobial Agents and Chemotherapy, 2002
• Nosocomial infections in medical intensive care units in the United States
  Critical Care Medicine, 1999
• The Economic Impact of Staphylococcus aureus Infection in New York City Hospitals
  Emerging Infectious Diseases, 1999
• From cost–effectiveness ratios to resource allocation: where to draw the line?
  1995